

Batch Release Certificate

Product name: Dextran 20 Pharmaceutical Quality

Specification No.: 40069

Batch No.: xxxxxx

Manufacturing date: mmmm_yyyy

Retest date (5 years): mmmm_yyyy

Manufacturing sites: Pharmacosmos A/S, Roervangsvej 30, DK-4300 Holbaek, Denmark

DKMA* No.: 254629

GMP certificate No.: DK API-H 00083617, DK API-V 00083617

FDA establishment No.: FEI 3002807874

FDA facility classification: Acceptable

EDQM* certificate No.: Certificates for Dextran 1, 40, 60 & 70 Ph.Eur. available

| Method: | Parameter: | Results of analysis: | Limits: |
|---------|-------------------------------------|----------------------|---------------------|
| EP | Appearance of solution: | Complies | Clear and colorless |
| EP | Acidity or Alkalinity: | Complies | Complies |
| EP | Specific rotation, (+/-) °: | +x | +191 – +201 |
| LI030-1 | Average molecular mass, Mw: | x,xxx | 17,000 – 23,000 |
| EP | Nitrogen containing substances, ppm | x | ≤110 |
| EP | Residual solvent % by GC: | Complies | ** Complies |
| EP | Loss on drying (105°C, 5h), % w/w: | x.x | ≤7.0 |
| EP | Sulphated ash, % w/w: | x.x | ≤0.3 |
| EP | Bacterial endotoxins, IU/g: | Complies | <25 |
| EP | Microbial contamination, cfu/g: | Complies | ≤100 |

References to official monographs are to be considered as current editions.

*) EDQM refers to 'European Directorate for the Quality of Medicines and Healthcare'. DKMA refers to 'Danish Medicines Agency'

**) Test for Residual solvents is not carried out according to approval from EDQM.

We hereby confirm that no class 1, class 2 and class 3 solvent, cf. EP 5.4 and USP <467> Residual solvents, is used in the manufacturing of this product.

We hereby confirm that no metal catalysts or metal reagents are used in the manufacturing of this product. Elemental impurities, cf. ICH Q3D are unlikely to be present.

CERTIFICATE OF CONFORMITY

I hereby certify that the above information is authentic and accurate. This batch of Active Pharmaceutical Ingredient has been manufactured, including packaging and quality control at the above mentioned site in full compliance with the GMP requirements for active starting materials and with the above mentioned specifications. The batch processing, packaging and analysis records were reviewed and found to be in compliance with GMP.

Date (dd.mm.yyyy):

Qualified Person, Heidi Skjødt Andersen, M.Sc. Pharm